{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-031241","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.180186+00:00","generated_at":"2026-05-14T22:34:26.991197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch","bullets":["Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.","NEREUS (tradipitant) launched via direct-to-consumer platform; first new motion sickness drug in 40+ years.","FY2026 revenue guidance raised to $240-290M from $230-260M, including $10-30M from NEREUS.","Net loss $48.6M ($0.82 diluted EPS) vs loss $29.5M ($0.50) in Q1 2025.","BYSANTI (milsaperidone) received FDA approval Feb 20 for bipolar I and schizophrenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-031241","json":"https://secwatch.observer/filing/0001628280-26-031241.json","markdown":"https://secwatch.observer/filing/0001628280-26-031241.md","text":"https://secwatch.observer/filing/0001628280-26-031241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:34:26.991197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"687a284791838b833f438af70664f18e0f5ec6a2","claim":"Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $51.7 million, net income net loss of $48.6 million (diluted loss per share of $0.82), EPS (diluted loss per share of $0.82). Guidance raised.","evidence_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001493152-26-026777","ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:40:33+00:00","headline":"INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026777","json":"https://secwatch.observer/filing/0001493152-26-026777.json","markdown":"https://secwatch.observer/filing/0001493152-26-026777.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"and technologies,\ntoday announced fiscal year 2025 financial results. FY2025\nFinancial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue\n was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated\n clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue\n from all clinics was $8,021,929, including","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm"}},{"accession":"0001493152-26-026770","ticker":"POLA","company_name":"Polar Power, Inc.","filed_at":"2026-06-02T12:30:26+00:00","headline":"Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026770","json":"https://secwatch.observer/filing/0001493152-26-026770.json","markdown":"https://secwatch.observer/filing/0001493152-26-026770.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm"}},{"accession":"0001104659-26-069202","ticker":"CTRN","company_name":"Citi Trends Inc","filed_at":"2026-06-02T10:58:00+00:00","headline":"Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069202","json":"https://secwatch.observer/filing/0001104659-26-069202.json","markdown":"https://secwatch.observer/filing/0001104659-26-069202.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/tm2616574d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"(EXHIBIT 99.1) ---\n\nEX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER\nFISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth\nof 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million;\nQ1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm"}},{"accession":"0000832988-26-000158","ticker":"SIG","company_name":"SIGNET JEWELERS LTD","filed_at":"2026-06-02T10:54:29+00:00","headline":"Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000832988-26-000158","json":"https://secwatch.observer/filing/0000832988-26-000158.json","markdown":"https://secwatch.observer/filing/0000832988-26-000158.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/sig-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"On June 2, 2026, Signet Jewelers Limited (the \"Company\") issued a press release announcing results for the first quarter ended May 2, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/832988/000083298826000158/0000832988-26-000158-index.htm"}},{"accession":"0001104659-26-069198","ticker":"DG","company_name":"DOLLAR GENERAL CORP","filed_at":"2026-06-02T10:54:17+00:00","headline":"Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance","event_type":"earnings","sec_items":["2.02","5.07","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069198","json":"https://secwatch.observer/filing/0001104659-26-069198.json","markdown":"https://secwatch.observer/filing/0001104659-26-069198.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/tm2616084d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026\nHighlights · Net\n Sales Increased 3.4% to $10.8 Billion · Same-Store\n Sales Increased 2.0% · Operating\n Profit Increased 10.8% to $638.5 Million · Diluted\n Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash\n Flow From","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29534/000110465926069198/0001104659-26-069198-index.htm"}},{"accession":"0001062993-26-002965","ticker":"HIVE","company_name":"HIVE Digital Technologies Ltd.","filed_at":"2026-06-02T10:23:19+00:00","headline":"HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002965","json":"https://secwatch.observer/filing/0001062993-26-002965.json","markdown":"https://secwatch.observer/filing/0001062993-26-002965.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/form8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1720424/000106299326002965/0001062993-26-002965-index.htm"}},{"accession":"0000029644-26-000049","ticker":"DCI","company_name":"DONALDSON Co INC","filed_at":"2026-06-01T21:41:36+00:00","headline":"Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029644-26-000049","json":"https://secwatch.observer/filing/0000029644-26-000049.json","markdown":"https://secwatch.observer/filing/0000029644-26-000049.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/dci-20260602.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"press release is furnished herewith as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nDonaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29644/000002964426000049/0000029644-26-000049-index.htm"}},{"accession":"0001104659-26-068983","ticker":"GMRS","company_name":"GMR Solutions Inc.","filed_at":"2026-06-01T20:45:55+00:00","headline":"GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068983","json":"https://secwatch.observer/filing/0001104659-26-068983.json","markdown":"https://secwatch.observer/filing/0001104659-26-068983.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/gmrs-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm","comparable_excerpt":"today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898718/000110465926068983/0001104659-26-068983-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}